Otten J - Search Results

1

Absorption, single-dose and steady-state metabolism, excretion, and pharmacokinetics of adagrasib, a KRAS^G12C inhibitor.

Rahbaek L, Cilliers C, Wegerski CJ, Nguyen N, Otten J, Hargis L, Marx MA, Christensen JG, Tran JQ. Rahbaek L, et al. Among authors: otten j. Cancer Chemother Pharmacol. 2024 Dec 19;95(1):7. doi: 10.1007/s00280-024-04728-7. Cancer Chemother Pharmacol. 2024. PMID: 39699634

2

Identification of the Clinical Development Candidate MRTX849, a Covalent KRAS^G12C Inhibitor for the Treatment of Cancer.

Fell JB, Fischer JP, Baer BR, Blake JF, Bouhana K, Briere DM, Brown KD, Burgess LE, Burns AC, Burkard MR, Chiang H, Chicarelli MJ, Cook AW, Gaudino JJ, Hallin J, Hanson L, Hartley DP, Hicken EJ, Hingorani GP, Hinklin RJ, Mejia MJ, Olson P, Otten JN, Rhodes SP, Rodriguez ME, Savechenkov P, Smith DJ, Sudhakar N, Sullivan FX, Tang TP, Vigers GP, Wollenberg L, Christensen JG, Marx MA. Fell JB, et al. Among authors: otten jn. J Med Chem. 2020 Jul 9;63(13):6679-6693. doi: 10.1021/acs.jmedchem.9b02052. Epub 2020 Apr 6. J Med Chem. 2020. PMID: 32250617 Free article.

3

An in vitro, high throughput, seven CYP cocktail inhibition assay for the evaluation of new chemical entities using LC-MS/MS.

Otten JN, Hingorani GP, Hartley DP, Kragerud SD, Franklin RB. Otten JN, et al. Drug Metab Lett. 2011 Jan;5(1):17-24. doi: 10.2174/187231211794455235. Drug Metab Lett. 2011. PMID: 21198441

4

Discovery of Pyrazolopyrazines as Selective, Potent, and Mutant-Active MET Inhibitors with Intracranial Efficacy.

Bumpers QA, Pipal RW, Benz-Weeden AM, Brewster JT 2nd, Cook A, Crooks AL, Cruz C, Dwulet NC, Gaudino JJ, Golec D, Harrison JA, Hartley DP, Hassanien SH, Hicken EJ, Kahn D, Laird ER, Lemieux C, Lewandowski N, McCown J, McDonald MG, McNulty O, Mou TC, Nguyen P, Oko L, Opie LP, Otten J, Peck SC, Polites VC, Randall SD, Rosen RZ, Savechenkov P, Simpson H, Singh A, Sparks D, Wickersham K, Wollenberg L, Wong CE, Wong J, Wu WI, Elsayed MSA, Hinklin RJ, Tang TP. Bumpers QA, et al. Among authors: otten j. J Med Chem. 2024 Aug 22;67(16):14466-14477. doi: 10.1021/acs.jmedchem.4c01232. Epub 2024 Aug 1. J Med Chem. 2024. PMID: 39088797

5

Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2.

Rhodes SP, Otten JN, Hingorani GP, Hartley DP, Franklin RB. Rhodes SP, et al. J Pharmacol Toxicol Methods. 2011 May-Jun;63(3):223-6. doi: 10.1016/j.vascn.2010.11.002. Epub 2010 Nov 24. J Pharmacol Toxicol Methods. 2011. PMID: 21111054

6

In silico modeling of p450 substrates, inhibitors, activators, and inducers.

DeLisle RK, Otten J, Rhodes S. DeLisle RK, et al. Among authors: otten j. Comb Chem High Throughput Screen. 2011 Jun 1;14(5):396-416. doi: 10.2174/138620711795508377. Comb Chem High Throughput Screen. 2011. PMID: 21470185 Review.

7

Identification of the Clinical Candidate PF-07284890 (ARRY-461), a Highly Potent and Brain Penetrant BRAF Inhibitor for the Treatment of Cancer.

Ren L, Moreno D, Baer BR, Barbour P, Bettendorf T, Bouhana K, Brown K, Brown SA, Fell JB, Hartley DP, Hicken EJ, Laird ER, Lee P, McCown J, Otten JN, Prigaro B, Wallace R, Kahn D. Ren L, et al. Among authors: otten jn. J Med Chem. 2024 Aug 8;67(15):13019-13032. doi: 10.1021/acs.jmedchem.4c00998. Epub 2024 Jul 30. J Med Chem. 2024. PMID: 39077892 Clinical Trial.

8

Discovery of 5-Azaquinoxaline Derivatives as Potent and Orally Bioavailable Allosteric SHP2 Inhibitors.

Elsayed MSA, Blake JF, Boys ML, Brown E, Chapsal BD, Chicarelli MJ, Cook AW, Fell JB, Fischer JP, Hanson L, Lemieux C, Martinson MC, McCown J, McNulty OT, Mejia MJ, Neitzel NA, Otten JN, Rodriguez ME, Wilcox D, Wong CE, Zhou Y, Hinklin RJ. Elsayed MSA, et al. Among authors: otten jn. ACS Med Chem Lett. 2023 Nov 15;14(12):1673-1681. doi: 10.1021/acsmedchemlett.3c00310. eCollection 2023 Dec 14. ACS Med Chem Lett. 2023. PMID: 38116446 Free PMC article.

9

Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones.

Wallace EM, Lyssikatos J, Blake JF, Seo J, Yang HW, Yeh TC, Perrier M, Jarski H, Marsh V, Poch G, Livingston MG, Otten J, Hingorani G, Woessner R, Lee P, Winkler J, Koch K. Wallace EM, et al. Among authors: otten j. J Med Chem. 2006 Jan 26;49(2):441-4. doi: 10.1021/jm050834y. J Med Chem. 2006. PMID: 16420026

10

8-Tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors.

Thomas AA, Hunt KW, Newhouse B, Watts RJ, Liu X, Vigers G, Smith D, Rhodes SP, Brown KD, Otten JN, Burkard M, Cox AA, Geck Do MK, Dutcher D, Rana S, DeLisle RK, Regal K, Wright AD, Groneberg R, Liao J, Scearce-Levie K, Siu M, Purkey HE, Lyssikatos JP. Thomas AA, et al. Among authors: otten jn. J Med Chem. 2014 Dec 11;57(23):10112-29. doi: 10.1021/jm5015132. Epub 2014 Nov 26. J Med Chem. 2014. PMID: 25411915

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

426 results

Search Page

Filters